The initial success of Sildenafil undeniably transformed the drug landscape, but placing funds in companies strongly reliant on off-patent versions presents a uncertain picture. While early profits were substantial, the cessation of patents and the emergence of cheaper alternatives have diminished sales. Therefore, a thorough assessment of ongoing